Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: CNS disorders therapeutics - AMRI/Bristol-Myers Squibb

Drug Profile

Research programme: CNS disorders therapeutics - AMRI/Bristol-Myers Squibb

Latest Information Update: 11 Nov 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Albany Molecular Research Inc
  • Developer AMRI; Bristol-Myers Squibb
  • Class
  • Mechanism of Action Biogenic amine uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued CNS disorders

Most Recent Events

  • 07 Nov 2013 Discontinued - Preclinical for CNS disorders in USA (unspecified route)
  • 27 May 2009 AMRI and Bristol-Myers Squibb continue to evaluate additional compounds in their ongoing research collaboration for CNS disorders
  • 27 May 2009 Bristol-Myers Squibb files a CTA with the MPA in Sweden to initiate phase I trials with a second biogenic amine reuptake inhibitor for CNS disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top